Opus Genetics (IRD) Accumulated Depreciation & Amortization (2013 - 2024)
Opus Genetics (IRD) reported Accumulated Depreciation & Amortization of $25000.0 for Q3 2024, up 13.64% year-over-year from $22000.0 in Q4 2023, and little changed on a QoQ basis from $25000.0 in Q2 2024.
Opus Genetics (IRD) has 12 years of Accumulated Depreciation & Amortization data on file, last reported at $25000.0 in Q3 2024.
- Quarterly Accumulated Depreciation & Amortization rose 13.64% year-over-year to $25000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $25000.0 (up 13.64% YoY) and the FY2023 annual result came in at $25000.0, up 31.58% from the prior year.
- Accumulated Depreciation & Amortization held at $25000.0 in Q3 2024 per IRD's latest filing, from $25000.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $298736.0 in Q3 2020 and bottomed at $11000.0 in Q4 2020.
- The 5-year median for Accumulated Depreciation & Amortization is $20000.0 (2023), against an average of $61468.2.
- The widest annual swing landed in 2020, when Accumulated Depreciation & Amortization surged 266.67%; it then sank 95.73% in 2021.
- Tracing IRD's Accumulated Depreciation & Amortization over 5 years: stood at $11000.0 in 2020, then soared by 36.36% to $15000.0 in 2021, then advanced by 26.67% to $19000.0 in 2022, then soared by 31.58% to $25000.0 in 2023, then changed by 0.0% to $25000.0 in 2024.
- Per Business Quant, the three latest IRD Accumulated Depreciation & Amortization figures stand at $25000.0 (Q3 2024), $25000.0 (Q2 2024), and $25000.0 (Q1 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 25,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Jun 30, 2024 | 25,000.00 |
| Jun 30, 2024 | 25,000.00 |
| Mar 31, 2024 | 25,000.00 |
| Mar 31, 2024 | 25,000.00 |
| Dec 31, 2023 | 25,000.00 |
| Dec 31, 2023 | 25,000.00 |
| Sep 30, 2023 | 22,000.00 |
| Sep 30, 2023 | 22,000.00 |
| Jun 30, 2023 | 21,000.00 |
| Jun 30, 2023 | 21,000.00 |
| Mar 31, 2023 | 20,000.00 |
| Mar 31, 2023 | 20,000.00 |
| Dec 31, 2022 | 19,000.00 |
| Dec 31, 2022 | 19,000.00 |
| Sep 30, 2022 | 18,000.00 |
| Sep 30, 2022 | 18,000.00 |
| Jun 30, 2022 | 17,000.00 |
| Jun 30, 2022 | 17,000.00 |
| Mar 31, 2022 | 16,000.00 |
| Mar 31, 2022 | 16,000.00 |
| Dec 31, 2021 | 15,000.00 |
| Dec 31, 2021 | 15,000.00 |
| Sep 30, 2021 | 14,000.00 |
| Sep 30, 2021 | 14,000.00 |
| Jun 30, 2021 | 13,000.00 |
| Jun 30, 2021 | 13,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Dec 31, 2020 | 11,000.00 |
| Dec 31, 2020 | 11,000.00 |
| Sep 30, 2020 | 298,736.00 |
| Sep 30, 2020 | 298,736.00 |
| Jun 30, 2020 | 290,181.00 |
| Jun 30, 2020 | 290,181.00 |
| Mar 31, 2020 | 280,978.00 |
| Mar 31, 2020 | 280,978.00 |
| Dec 31, 2019 | 3,000.00 |
| Dec 31, 2019 | 3,000.00 |
| Sep 30, 2019 | 277,623.00 |
| Sep 30, 2019 | 277,623.00 |
| Jun 30, 2019 | 268,240.00 |
| Jun 30, 2019 | 268,240.00 |
| Mar 31, 2019 | 283,499.00 |
| Mar 31, 2019 | 283,499.00 |
| Dec 31, 2018 | 709,117.00 |
| Dec 31, 2018 | 709,117.00 |
| Sep 30, 2018 | 698,110.00 |
| Sep 30, 2018 | 698,110.00 |
| Jun 30, 2018 | 688,093.00 |
| Jun 30, 2018 | 688,093.00 |
| Mar 31, 2018 | 675,505.00 |
| Mar 31, 2018 | 675,505.00 |
| Dec 31, 2017 | 711,846.00 |
| Dec 31, 2017 | 711,846.00 |
| Sep 30, 2017 | 700,451.00 |
| Sep 30, 2017 | 700,451.00 |
| Jun 30, 2017 | 689,438.00 |
| Jun 30, 2017 | 689,438.00 |
| Mar 31, 2017 | 678,415.00 |
| Mar 31, 2017 | 678,415.00 |
| Dec 31, 2016 | 669,488.00 |
| Dec 31, 2016 | 669,488.00 |
| Sep 30, 2016 | 660,695.00 |
| Sep 30, 2016 | 660,695.00 |
| Jun 30, 2016 | 651,625.00 |
| Jun 30, 2016 | 651,625.00 |
| Mar 31, 2016 | 642,733.00 |
| Mar 31, 2016 | 642,733.00 |
| Dec 31, 2015 | 636,572.00 |
| Dec 31, 2015 | 636,572.00 |
| Sep 30, 2015 | 629,016.00 |
| Sep 30, 2015 | 629,016.00 |
| Jun 30, 2015 | 621,717.00 |
| Jun 30, 2015 | 621,717.00 |
| Mar 31, 2015 | 615,239.00 |
| Mar 31, 2015 | 615,239.00 |
| Dec 31, 2014 | 609,074.00 |
| Dec 31, 2014 | 609,074.00 |
| Sep 30, 2014 | 603,167.00 |
| Sep 30, 2014 | 603,167.00 |
| Jun 30, 2014 | 599,423.00 |
| Jun 30, 2014 | 599,423.00 |
| Mar 31, 2014 | 589,793.00 |
| Mar 31, 2014 | 589,793.00 |
| Dec 31, 2013 | 580,749.00 |
| Dec 31, 2013 | 580,749.00 |